Tandem Diabetes Care (TNDM) EBITDA Margin (2013 - 2026)

Tandem Diabetes Care has reported EBITDA Margin for 14 years, with the latest figure at 8.47% in Q1 2026.

• For the quarter ending Q1 2026, EBITDA Margin rose 4636.0% year-over-year to 8.47%; the trailing twelve-month figure through Mar 2026 stood at 8.72% (up 989.0% YoY), and the FY2025 full-year result was 19.43%, down 886.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 8.47%, down from 0.06% in the prior quarter.
• The five-year high for EBITDA Margin was 0.06% in Q4 2025, with the low at 72.11% in Q1 2023.
• Historically, EBITDA Margin has averaged 18.17% across 5 years, with a median of 13.43% in 2023.
• Annual changes were most pronounced in 2023 — EBITDA Margin plunged 6236 bps — and 2024, when it jumped 4863 bps.
• Tandem Diabetes Care's EBITDA Margin stood at 5.72% in 2022, then plunged by 135 bps to 13.43% in 2023, then soared by 87 bps to 1.79% in 2024, then surged by 97 bps to 0.06% in 2025, then sank by 14899 bps to 8.47% in 2026.
• The last three EBITDA Margin figures came in at 8.47% (Q1 2026), 0.06% (Q4 2025), and 7.92% (Q3 2025), per Business Quant data.